Physician profile
Dionicio M Alvarez
NPI 1275504490
$8,924.36
in general payments reported to CMS, 2019-2025
37 companies · $1,357 in 2025
The $1,357 reported for 2025 was more than what 84% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,118 · 2020: $636 · 2021: $1,123 · 2022: $2,000 · 2023: $1,320 · 2024: $1,370 · 2025: $1,357.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,995 · Education: $52.96.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,995.09 |
| Education | $52.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $1,597.64 | 2019-2025 | Farxiga, Lokelma |
| Vifor Pharma, INC. | $1,445.67 | 2019-2025 | Veltassa, Korsuva |
| Amgen INC. | $728.72 | 2019-2025 | Krystexxa, Tavneos |
| Bayer Healthcare Pharmaceuticals INC. | $547.49 | 2021-2025 | |
| Otsuka America Pharmaceutical, INC. | $514.09 | 2020-2025 | Jynarque |
| Glaxosmithkline, LLC. | $442.90 | 2021-2025 | Benlysta |
| Travere Therapeutics, INC. | $380.94 | 2022-2025 | |
| Ardelyx, INC. | $342.27 | 2024-2025 | Ibsrela |
| Akebia Therapeutics INC | $311.28 | 2019-2022 | |
| Calliditas Therapeutics US INC. | $303.64 | 2022-2025 | Tarpeyo |
| Nxstage Medical, INC. | $276.34 | 2020-2022 | |
| Horizon Therapeutics Plc | $274.11 | 2021-2023 | Krystexxa |
| Takeda Pharmaceuticals U.S.A., INC. | $166.24 | 2020-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $160.38 | 2023-2025 | Jardiance |
| Abbott Laboratories | $137.63 | 2021-2022 |
Show all 37 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dionicio Alvarez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.